fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Lamivudine & zidovudine

All products: general benefit

Combivir · DIN 02239213 · 150 mg & 300 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-12-31 — choose a marketed DIN from the same-category list.Discontinued December 31, 2024 · checked November 19, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-12-31 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-12-31 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Combivir · DIN 02239213 Manufacturer: ViiV Healthcare ULC; listing date 1999-09-15 Health Canada: Cancelled post market since 2024-12-31 · brand COMBIVIR · ATC J05AR01 ZIDOVUDINE AND LAMIVUDINE · form Tablet · route Oral · ingredients LAMIVUDINE 150 MG, ZIDOVUDINE 300 MG · company Viiv healthcare ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02239213)

Source record
DIN 02239213: Combivir Raw flags: sec3=Y Item: 081800049; group id 95; item number 0167; lccId None; manufacturer id VIH Source form: Tab; strength: 150mg & 300mg Recorded listing: General benefit Source prices (unrounded): $13.2262; ministry $2.6103 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02239213 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62673
Interchangeable products
Apo-Lamivudine-Zidovudine · DIN 02375540 · $2.6103 Auro-Lamivudine/Zidovudine · DIN 02414414 · $2.6103 Jamp Lamivudine / Zidovudine · DIN 02502801 · $2.6103
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since December 31, 2024 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (J05AR): coverage varies; not interchangeable

  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit
  • Abacavir + lamivudine (Kivexa): general benefit
  • Bictegravir + emtricitabine + tenofovir alafenamide hemifumarate (Biktarvy): general benefit
  • Cabotegravir + rilpivirine (Cabenuva): general benefit
  • Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil (Stribild): general benefit
  • Cobicistat + darunavir (Prezcobix): general benefit

48 more in the class list below

Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR & RILPIVIRINE

· 2 products · General benefit · strengths: 200mg/mL & 300mg/mL · Inj Sol-2mL Kit, Inj Sol-3mL Kit

COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE

· 1 products · General benefit · strengths: 150mg & 150mg & 200mg & 300mg · Tab

DARUNAVIR & COBICISTAT

· 1 products · General benefit · strengths: 800mg & 150mg · Tab

DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE

· 1 products · General benefit · strengths: 800mg & 150mg & 200mg & 10mg · Tab

DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE

· 1 products · General benefit · strengths: 50mg & 600mg & 300mg · Tab

DOLUTEGRAVIR & RILPIVIRINE

· 1 products · General benefit · strengths: 50mg & 25mg · Tab

DOLUTEGRAVIR SODIUM/LAMIVUDINE

· 1 products · General benefit · strengths: 50mg & 300mg · Tab

DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE

· 1 products · General benefit · strengths: 100mg & 300mg & 300mg · Tab

EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE

· 7 products · General benefit · strengths: 600mg/300mg/200mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:18 and 42 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS APO-LAMIVUDINE-ZIDOVUDINE (lamivudine and zidovudine), in combination with other antiretrovirals, is indicated for the treatment of HIV infection. 1.1 Pediatrics Pediatrics (< 12 years of age): The safety and efficacy of lamivudine and zidovudine tablets in pediatric patients less than 12 years of age have not been established. APO-LAMIVUDINE- ZIDOVUDINE is not recommended in children less than 12 years of age, as appropriate dose reduction for the weight of the child cannot be made. (see 4 DOSAGE AND ADMINISTRATION section). 1.2 Geriatrics Geriatrics (> 65 years of age): No specific data are available, however special care is advised in this age group due to age associated changes such as the decrease in renal function and alteration of hematological parameters. https://pdf.hres.ca/dpd_pm/00071412.PDF PM date: APR 27, 2012 Source product: APO-LAMIVUDINE-ZIDOVUDINE; DIN 02375540; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18